Piper Sandler Maintains Neutral on Edwards Lifesciences, Lowers Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Adam Maeder maintains a Neutral rating on Edwards Lifesciences and lowers the price target from $73 to $70.
October 25, 2024 | 2:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler has maintained a Neutral rating on Edwards Lifesciences but has lowered the price target from $73 to $70, indicating a slightly less optimistic outlook.
The lowering of the price target from $73 to $70 by Piper Sandler suggests a slightly less optimistic view on Edwards Lifesciences' stock performance. This could lead to a short-term negative impact on the stock price as investors may adjust their expectations.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100